Corporate physiotherapy outcomes: measure what changed, not what you hope it saved

Two burden indicators, two different measures

Corporate physiotherapy is often asked to do several jobs at once: relieve symptoms, help employees function at work, reduce absence, and support safer work. Those are different outcomes. A credible evaluation starts by deciding which question the programme is designed to answer, then measures clinical health and work participation separately. It does not turn a lower pain score into proof of fewer lost days, higher productivity, or a financial return. These figures describe context, not the likely caseload or effect of a company's physiotherapy service.

Why the evidence calls for restraint

A systematic review and meta-analysis of 20 randomized trials included 5,753 people on long-term sick leave or considered at risk. At 12 months, multidisciplinary rehabilitation versus usual care showed no clear difference in return to work: RR 1.01 (95% CI 0.70–1.48). The interval includes no difference and allows meaningfully lower or higher relative return-to-work rates; it is not evidence of equivalence. The review found no conclusive evidence identifying the most effective work-related intervention, and certainty ranged from very low to moderate. Its population and interventions are not the same as a general corporate physiotherapy or wellness programme. Tingulstad et al., 2022

Clinical symptom changes also cannot stand in for workplace outcomes. For example, a 20-week cluster randomized trial of 351 office workers reported changes in self-reported neck pain and headache with workplace strength training; headache intensity was lower by 1.1 points (reported ±0.2) versus reference in both exercise groups. The trial's reported outcomes were symptoms, not absence or productivity; the ± values in the abstract are not 95% confidence intervals. Gram et al.

A practical corporate scorecard

Start with a logic model: who is eligible, what service is offered, what employees actually receive, what changes are expected, and over what period. MRC process-evaluation guidance recommends measuring implementation, mechanisms and context as well as outcomes; CDC workplace-program guidance likewise frames evaluation as part of a local assess–plan–implement–evaluate cycle. These are evaluation frameworks, not evidence that any particular physiotherapy programme works. MRC guidance; CDC workplace programme guidance

Baseline, follow-up and comparison design

Before launch, define one or two primary questions—for example, whether the service reaches the intended groups, whether participants' function changes, or whether work absence differs from a credible comparison group. Collect baseline measures before treatment, repeat the same measures at prespecified follow-ups, and state the observation windows. A practical plan might include an end-of-care follow-up and a later check, but intervals should follow the intervention and clinical question, not a universal template.

A descriptive before-and-after report can show service reach, completion and change among measured participants. It cannot, by itself, show that physiotherapy caused the change: symptoms can fluctuate, employees may seek care when symptoms peak, staffing and seasonality change, and other safety or work-modification initiatives may occur at the same time. Where feasible, use randomized allocation or a credible phased rollout, matched comparison or other quasi-experimental design. Predefine eligibility, outcomes, analysis, handling of missing data and subgroup reporting. Adjust or stratify for relevant case mix and work context, and report effect estimates with confidence intervals rather than only percentages or p-values.

Costs are not automatically ROI

An employer can calculate programme costs and describe cost-consequence results without claiming a return. If estimating cost-effectiveness or ROI, specify the employer or societal perspective, time horizon, comparison, included costs, valuation of time, attribution assumptions and sensitivity analyses. A pain score, a self-reported productivity percentage, or a before-and-after absence change is not itself a cash saving caused by treatment. Report uncertainty and avoid a universal ROI promise: the reviewed evidence does not establish one.

Evidence used and limitations

This draft uses Eurostat's 2020 self-reported EU-LFS measure, the BLS 2021–2022 employer-reported DAFW series, the 2022 RCT systematic review of work-related return-to-work interventions, a workplace exercise RCT, and MRC/CDC evaluation guidance. The burden values are deliberately shown in separate rows because populations, definitions, periods and denominators differ. The RTW estimate is presented as uncertain, not as proof for or against an individual service.